TITAN-HCC: Testing immunotherapy plus TACE for liver cancer beyond standard criteria
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that is either confirmed by biopsy or meets standard clinical criteria.
- Your liver cancer is at an early or intermediate stage (BCLC A or B) but is too large or numerous for a standard liver transplant (beyond Milan criteria), and a team of doctors believes surgery can be done with a goal of cure.
- You are able to undergo a procedure called TACE (a targeted chemotherapy injection into the liver).
- Your liver function is good (Child-Pugh score 7 or less, meaning your liver is working relatively well).
- Your overall health status is good (ECOG performance status 0 or 1, meaning you can take care of yourself and are up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This study tests a combination of a liver-directed treatment (TACE) with two immunotherapy drugs and bevacizumab for patients with liver cancer that cannot be surgically removed but has not spread outside the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.